Not Applicable
Not Applicable
In some embodiments this invention relates to implantable medical devices, their manufacture, and methods of use. Some embodiments are directed to delivery systems, such as catheter systems of all types, which are utilized in the delivery of such devices.
A stent is a medical device introduced to a body lumen and is well known in the art. Typically, a stent is implanted in a blood vessel at the site of a stenosis or aneurysm endoluminally, i.e. by so-called “minimally invasive techniques” in which the stent in a radially reduced configuration, optionally restrained in a radially compressed configuration by a sheath and/or catheter, is delivered by a stent delivery system or “introducer” to the site where it is required. The introducer may enter the body from an access location outside the body, such as through the patient's skin, or by a “cut down” technique in which the entry blood vessel is exposed by minor surgical means.
Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices, collectively referred to hereinafter as stents, are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. Stents may be used to reinforce body vessels and to prevent restenosis following angioplasty in the vascular system. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).
Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.
Within the vasculature it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.
The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention.
All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.
Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.
A brief abstract of the technical disclosure in the specification is provided as well only for the purposes of complying with 37 C.F.R. 1.72. The abstract is not intended to be used for interpreting the scope of the claims.
In at least one embodiment, the invention is directed to a stent assembly having a main body with a proximal main body, a contralateral main body, and a distal main body at least partially constructed of interconnected struts connected one to another by a peak wherein the distal main body has a greater peak width to strut width ratio than does the proximal main body and contralateral main body. In at least one embodiment, a branch portion may be in fluid communication with the main body such that in the expanded state the branch portion extends at an oblique angle in relation to the longitudinal axis. In at least one embodiment the branch portion extends from the contralateral main body.
In at least one embodiment, the peak width to strut width ratio of the distal main body is about 3 to 1. Other ratios include 1.1:1, 1.25:1, 1.5:1.75:1, 2:1, 2.5:1, 3.5:1, etc.
In at least one embodiment, the peaks in the distal main body have a greater strain concentration than does the rest of the stent.
In at least one embodiment, the stent assembly may be disposed about at least one catheter balloon.
In at least one embodiment, the branch portion may be deployed using a second balloon.
In at least one embodiment, the distal main body may comprise at least one third of the length of the stent assembly.
In at least one embodiment, the struts of the distal main body may be narrower than the struts of the rest of the stent.
In at least one embodiment, the peaks of the distal main body may be wider than the peaks of the rest of the stent.
In at least one embodiment, the stent assembly may be secured to the catheter only in the distal main body.
In at least one embodiment, the stent assembly may be secured to a catheter in at least one of the proximal main body, the contralateral main body, and the distal main body.
In at least one embodiment, the stent assembly may comprise a plurality of annular bands having a serpentine configuration.
In at least one embodiment, the annular bands of the distal main body may have a smaller number of peaks than the annular bands of the proximal main body and the contralateral main body.
In at least one embodiment, the proximal main body, the contralateral main body, and the branch portion may have the substantially same peak width to strut width ratio.
In at least one embodiment, the peaks in the distal main body are at least twice as wide as the struts of the distal main body.
In at least one embodiment of the invention a method of securing a stent assembly to a catheter balloon comprises providing a stent assembly as described above, disposing the stent assembly about a catheter balloon and a branch balloon, and securing the peaks and/or struts of the distal main body of the stent assembly to the catheter balloon. In at least one embodiment, the struts and peaks of the distal main body may be secured to the catheter balloon by plastically deforming the struts and peaks. Plastically deforming the stent struts and/or peaks may prevent them from elastically recoiling away from the balloon. By preventing this recoil, the mechanical interaction between the stent struts/peaks and balloon material may resist movement of the stent in relation to the balloon when an external force is applied.
These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for further understanding of the invention, its advantages and objectives obtained by its use, reference should be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described an embodiments of the invention.
A detailed description of the invention is hereafter described with specific reference being made to the drawings.
a is a side view of a peak in the proximal main body.
b is a side view of a peak in the distal main body.
While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.
For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.
In
In some embodiments as shown in
The main body 12 may be constructed of interconnected bands.
In
The higher securement of the peak portions 37 in the distal main body 30 improves the securement of the entire stent assembly 10 as the securement of a bifurcated stent is dependent on the interaction between only the distal end of the stent interacting with the delivery balloon. In some embodiments the peak width to strut width ratio is 3 to 1. In some instances it is at least 2 to 1.
In some embodiments, the peaks in the distal main body have a width that is equal to or less than the width of the peaks in the rest of the stent. In such embodiments, the increased peak width to strut width ratio is maintained by strut widths in the distal main body that are proportionally narrower than the strut widths in the rest of the stent. In some embodiments, the stent assembly may be secured to the balloon in only the distal main body. In some embodiments, securement to the balloon is present in other parts of the stent assembly.
In some embodiments, the number of peaks in one annular band may be greater than the number of peaks in another annular band. In some embodiments, the annular bands of the distal main body have a smaller number of peaks in the annular bands than in other parts of the stent assembly.
In some embodiments as shown in
As shown in
The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.
In some embodiments at least a portion of the stent assembly is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto. The therapeutic agent can be applied in a variety of ways and can include therapeutic agent being applied in some locations more than others.
A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.
The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy and nickel-titanium alloys, for example, Nitinol.
The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon being heated to a transition temperature and having any restraints removed therefrom.
In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.
Further, the particular features presented in the dependent claims may be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.
This completes the description of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.
Number | Name | Date | Kind |
---|---|---|---|
4309994 | Grunwald | Jan 1982 | A |
4769005 | Ginsburg et al. | Sep 1988 | A |
4774949 | Fogarty | Oct 1988 | A |
4896670 | Crittenden | Jan 1990 | A |
4905667 | Foerster et al. | Mar 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5342387 | Summers | Aug 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5476471 | Shifrin et al. | Dec 1995 | A |
5487730 | Marcadis et al. | Jan 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5609605 | Marshall et al. | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5669932 | Fischell et al. | Sep 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683450 | Goicoechea et al. | Nov 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5707348 | Krogh | Jan 1998 | A |
5709713 | Evans et al. | Jan 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755734 | Richter et al. | May 1998 | A |
5755735 | Richter et al. | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5827320 | Richter et al. | Oct 1998 | A |
5851464 | Davila et al. | Dec 1998 | A |
5868777 | Lam | Feb 1999 | A |
5893887 | Jayaraman | Apr 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5922020 | Klein et al. | Jul 1999 | A |
5961548 | Shmulewitz | Oct 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
6013054 | Jiun Yan | Jan 2000 | A |
6013091 | Ley et al. | Jan 2000 | A |
6017324 | Tu et al. | Jan 2000 | A |
6017363 | Hojeibane | Jan 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6033433 | Ehr et al. | Mar 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6048361 | Von Oepen | Apr 2000 | A |
6056775 | Borghi et al. | May 2000 | A |
6059824 | Taheri | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6086611 | Duffy et al. | Jul 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099497 | Adams et al. | Aug 2000 | A |
6113579 | Eidenschink et al. | Sep 2000 | A |
6117117 | Mauch | Sep 2000 | A |
6117156 | Richter et al. | Sep 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6129754 | Kanesaka et al. | Oct 2000 | A |
6142973 | Carleton et al. | Nov 2000 | A |
6143002 | Vietmeier | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6168621 | Vrba | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6210380 | Mauch | Apr 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6210433 | Larre | Apr 2001 | B1 |
6254593 | Wilson | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264662 | Lauterjung | Jul 2001 | B1 |
6264686 | Rieu et al. | Jul 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6293968 | Taheri | Sep 2001 | B1 |
6325822 | Chouinard et al. | Dec 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6334870 | Ehr et al. | Jan 2002 | B1 |
6346089 | Dibie | Feb 2002 | B1 |
6355060 | Lenker et al. | Mar 2002 | B1 |
6361544 | Wilson et al. | Mar 2002 | B1 |
6361555 | Wilson | Mar 2002 | B1 |
6383213 | Wilson et al. | May 2002 | B2 |
6395018 | Castaneda | May 2002 | B1 |
6416543 | Hilaire et al. | Jul 2002 | B1 |
6436104 | Hojeibane | Aug 2002 | B2 |
6436134 | Richter et al. | Aug 2002 | B2 |
6508836 | Wilson et al. | Jan 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6540774 | Cox | Apr 2003 | B1 |
6540779 | Richter et al. | Apr 2003 | B2 |
6579309 | Loos et al. | Jun 2003 | B1 |
6579312 | Wilson et al. | Jun 2003 | B2 |
6582394 | Reiss et al. | Jun 2003 | B1 |
6596020 | Vardi et al. | Jul 2003 | B2 |
6599315 | Wilson | Jul 2003 | B2 |
6599316 | Vardi et al. | Jul 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6689156 | Davidson et al. | Feb 2004 | B1 |
6692483 | Vardi et al. | Feb 2004 | B2 |
6695877 | Brucker et al. | Feb 2004 | B2 |
6706062 | Vardi et al. | Mar 2004 | B2 |
6749628 | Cho et al. | Jun 2004 | B1 |
6776793 | Brown et al. | Aug 2004 | B2 |
6811566 | Penn et al. | Nov 2004 | B1 |
6835203 | Vardi et al. | Dec 2004 | B1 |
6852124 | Cox et al. | Feb 2005 | B2 |
6858038 | Heuser | Feb 2005 | B2 |
6884258 | Vardi et al. | Apr 2005 | B2 |
6896699 | Wilson et al. | May 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6955687 | Richter et al. | Oct 2005 | B2 |
6955688 | Wilson et al. | Oct 2005 | B2 |
6962602 | Vardi et al. | Nov 2005 | B2 |
7018400 | Lashinski et al. | Mar 2006 | B2 |
7056323 | Mareiro et al. | Jun 2006 | B2 |
7060091 | Killion et al. | Jun 2006 | B2 |
20010003161 | Vardi et al. | Jun 2001 | A1 |
20010004706 | Hojeibane | Jun 2001 | A1 |
20010004707 | Dereume et al. | Jun 2001 | A1 |
20010012927 | Mauch | Aug 2001 | A1 |
20010016766 | Vardi et al. | Aug 2001 | A1 |
20010016767 | Wilson et al. | Aug 2001 | A1 |
20010016768 | Wilson et al. | Aug 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010027291 | Shanley | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010029396 | Wilson et al. | Oct 2001 | A1 |
20010037116 | Wilson et al. | Nov 2001 | A1 |
20010037138 | Wilson et al. | Nov 2001 | A1 |
20010039448 | Dibie | Nov 2001 | A1 |
20010049552 | Richter et al. | Dec 2001 | A1 |
20010056297 | Hojeibane | Dec 2001 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020013619 | Shanley | Jan 2002 | A1 |
20020022874 | Wilson | Feb 2002 | A1 |
20020026232 | Marotta et al. | Feb 2002 | A1 |
20020035392 | Wilson | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020052648 | McGuckin, Jr. et al. | May 2002 | A1 |
20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
20020095140 | Lootz et al. | Jul 2002 | A1 |
20020111675 | Wilson | Aug 2002 | A1 |
20020156516 | Vardi et al. | Oct 2002 | A1 |
20020156517 | Perouse | Oct 2002 | A1 |
20020165604 | Shanley | Nov 2002 | A1 |
20020173835 | Bourang et al. | Nov 2002 | A1 |
20020173840 | Brucker et al. | Nov 2002 | A1 |
20020183763 | Callol et al. | Dec 2002 | A1 |
20020193872 | Trout, III et al. | Dec 2002 | A1 |
20020193873 | Brucker et al. | Dec 2002 | A1 |
20030009209 | Hojeibane | Jan 2003 | A1 |
20030028233 | Vardi et al. | Feb 2003 | A1 |
20030050688 | Fischell et al. | Mar 2003 | A1 |
20030055378 | Wang et al. | Mar 2003 | A1 |
20030055483 | Gumm | Mar 2003 | A1 |
20030074047 | Richter | Apr 2003 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030097169 | Brucker | May 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030135259 | Simso | Jul 2003 | A1 |
20030181923 | Vardi | Sep 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20040002753 | Burgermeister et al. | Jan 2004 | A1 |
20040006381 | Sequin et al. | Jan 2004 | A1 |
20040015227 | Vardi et al. | Jan 2004 | A1 |
20040044396 | Clerc et al. | Mar 2004 | A1 |
20040059406 | Cully et al. | Mar 2004 | A1 |
20040088007 | Eidenschink | May 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040133268 | Davidson et al. | Jul 2004 | A1 |
20040138732 | Suhr et al. | Jul 2004 | A1 |
20040138737 | Davidson et al. | Jul 2004 | A1 |
20040148006 | Davidson et al. | Jul 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040186560 | Alt | Sep 2004 | A1 |
20040225345 | Fischell et al. | Nov 2004 | A1 |
20040267352 | Davidson et al. | Dec 2004 | A1 |
20050004656 | Das | Jan 2005 | A1 |
20050010278 | Vardi et al. | Jan 2005 | A1 |
20050015108 | Williams et al. | Jan 2005 | A1 |
20050015135 | Shanley | Jan 2005 | A1 |
20050060027 | Khenansho et al. | Mar 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050102021 | Osborne | May 2005 | A1 |
20050102023 | Yadin et al. | May 2005 | A1 |
20050119731 | Brucker et al. | Jun 2005 | A1 |
20050125076 | Ginn | Jun 2005 | A1 |
20050131526 | Wong | Jun 2005 | A1 |
20050149161 | Eidenschink et al. | Jul 2005 | A1 |
20050154442 | Eidenschink et al. | Jul 2005 | A1 |
20050154444 | Quadri | Jul 2005 | A1 |
20050183259 | Eidenschink et al. | Aug 2005 | A1 |
20050209673 | Shaked | Sep 2005 | A1 |
20050228483 | Kaplan et al. | Oct 2005 | A1 |
20050273157 | Pinchasik | Dec 2005 | A1 |
20060030924 | Van Der Leest et al. | Feb 2006 | A1 |
20060036315 | Yadin et al. | Feb 2006 | A1 |
20060041303 | Israel | Feb 2006 | A1 |
20060079956 | Eigler et al. | Apr 2006 | A1 |
20060173528 | Feld et al. | Aug 2006 | A1 |
20060271152 | Hilaire et al. | Nov 2006 | A1 |
20060287707 | Roeder et al. | Dec 2006 | A1 |
20070073376 | Krolik et al. | Mar 2007 | A1 |
20080132994 | Burgermeister et al. | Jun 2008 | A1 |
Number | Date | Country |
---|---|---|
2220864 | Jul 1999 | CA |
9014845 | Feb 1991 | DE |
29701758 | Mar 1997 | DE |
29701883 | May 1997 | DE |
0479730 | Oct 1991 | EP |
0751752 | Jan 1997 | EP |
0783873 | Jul 1997 | EP |
0804907 | Nov 1997 | EP |
0479557 | Jul 1998 | EP |
0876805 | Nov 1998 | EP |
0880949 | Dec 1998 | EP |
0891751 | Jan 1999 | EP |
0 895 759 | Feb 1999 | EP |
0904745 | Mar 1999 | EP |
0937442 | Aug 1999 | EP |
0347023 | Dec 1999 | EP |
1031328 | Aug 2000 | EP |
1031329 | Aug 2000 | EP |
0883384 | Dec 2000 | EP |
0862392 | Aug 2001 | EP |
0808140 | Dec 2001 | EP |
0884028 | Feb 2002 | EP |
1 190 685 | Mar 2002 | EP |
0897700 | Jul 2002 | EP |
0684022 | Feb 2004 | EP |
1157674 | Jul 2005 | EP |
1031330 | Nov 2005 | EP |
1070513 | Jun 2006 | EP |
2678508 | Jan 1993 | FR |
2740346 | Oct 1995 | FR |
2756173 | Nov 1996 | FR |
2337002 | May 1998 | GB |
8806026 | Aug 1988 | WO |
9521592 | Aug 1995 | WO |
9629955 | Oct 1996 | WO |
9634580 | Nov 1996 | WO |
9641592 | Dec 1996 | WO |
9707752 | Mar 1997 | WO |
9715346 | May 1997 | WO |
9716217 | May 1997 | WO |
9726936 | Jul 1997 | WO |
9741803 | Nov 1997 | WO |
9745073 | Dec 1997 | WO |
9746174 | Dec 1997 | WO |
9819628 | May 1998 | WO |
9836709 | Aug 1998 | WO |
9837833 | Sep 1998 | WO |
9847447 | Oct 1998 | WO |
9848879 | Nov 1998 | WO |
9903426 | Jan 1999 | WO |
9904726 | Feb 1999 | WO |
9915103 | Apr 1999 | WO |
9915109 | Apr 1999 | WO |
9924104 | May 1999 | WO |
9934749 | Jul 1999 | WO |
9936002 | Jul 1999 | WO |
9936015 | Jul 1999 | WO |
9944539 | Sep 1999 | WO |
9956661 | Nov 1999 | WO |
9965419 | Dec 1999 | WO |
0007523 | Feb 2000 | WO |
0010489 | Mar 2000 | WO |
0016719 | Mar 2000 | WO |
0027307 | May 2000 | WO |
0027463 | May 2000 | WO |
0028922 | May 2000 | WO |
0145594 | Jun 2000 | WO |
0044307 | Aug 2000 | WO |
0044309 | Aug 2000 | WO |
0047134 | Aug 2000 | WO |
0048531 | Aug 2000 | WO |
0049951 | Aug 2000 | WO |
0051523 | Sep 2000 | WO |
0057813 | Oct 2000 | WO |
0067673 | Nov 2000 | WO |
0071055 | Nov 2000 | WO |
WO 0071054 | Nov 2000 | WO |
0074595 | Dec 2000 | WO |
0121095 | Mar 2001 | WO |
0121109 | Mar 2001 | WO |
0121244 | Mar 2001 | WO |
0135715 | May 2001 | WO |
0135863 | May 2001 | WO |
0139697 | Jun 2001 | WO |
0139699 | Jun 2001 | WO |
0141677 | Jun 2001 | WO |
0143665 | Jun 2001 | WO |
0143809 | Jun 2001 | WO |
0145785 | Jun 2001 | WO |
0149342 | Jul 2001 | WO |
0154621 | Aug 2001 | WO |
0154622 | Aug 2001 | WO |
0158385 | Aug 2001 | WO |
0160284 | Aug 2001 | WO |
0170294 | Sep 2001 | WO |
0170299 | Sep 2001 | WO |
0174273 | Oct 2001 | WO |
0189409 | Nov 2001 | WO |
0200138 | Jan 2002 | WO |
02053066 | Jul 2002 | WO |
02068012 | Sep 2002 | WO |
WO 03007842 | Jan 2003 | WO |
03055414 | Jul 2003 | WO |
03063924 | Aug 2003 | WO |
2004026174 | Apr 2004 | WO |
2004026180 | Apr 2004 | WO |
2005009295 | Feb 2005 | WO |
2005014077 | Feb 2005 | WO |
2006028925 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20070213811 A1 | Sep 2007 | US |